Virksomhedsform
Aktieselskab
Etableret
1975
Størrelse
Små
Ansatte
49
Omsætning
606 MDKK
Bruttofortj.
83 MDKK
Primært resultat (EBIT)
34 MDKK
Årets resultat
21 MDKK
Egenkapital
70 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
122/4.218
"Top 10%"
Rang i Danmark
6.529/342.443
"Top 10%"

Direktion top 3

Bestyrelse top 3

Jose Daniel Lucas Guerrero 1Bestyrelsesformand
Lone Rosenørn Jakobsen 1Bestyrelsesmedlem
Helene Rathkjen 1Bestyrelsesmedlem

Legale ejere top 3

Tegningsregler

Selskabet tegnes af en direktør, af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.

Stamoplysninger baseret på CVR

NavnEli Lilly Danmark A/S
BinavneEli Lilly Export A/S, Gemelli A/S, Cpi Norden A/S, Dista Products A/S, Elanco A/S, Elanco Animal Health A/S, Guidant A/S Vis mere
CVR51619811
AdresseLyskær 3E, 2 tv, 2730 Herlev
BrancheEngroshandel med medicinalvarer og sygeplejeartikler [464610]
Etableret31-01-1975 (49 år)
VirksomhedsformAktieselskab
Antal ansatte68 (årsværk:62)
ReklamebeskyttelseNej
RevisorEy Godkendt Revisionspartnerselskab siden 10-10-2014
Regnskabsperiode01-01 til 31-12
BankforbindelseBNP Paribas Fortis
Selskabskapital10.000.000 DKK
7.250.000 DKK (22-12-2000 - 18-12-2002)
6.250.000 DKK (06-12-1988 - 21-12-2000)
8.000.000 DKK (30-08-1987 - 05-12-1988)
Vedtægter seneste29-08-2022

Formål

Selskabets formål er at drive handel og fabrikation samt hermed beslægtet virksomhed.

Regnskab

 202220212020
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
605.577
+4%
581.520
+9%
531.908
+1%
Bruttofortjeneste
83.217
+18%
70.469
+3%
68.736
+2%
Årets resultat
21.095
+24%
17.045
+69%
10.108
-96%
Egenkapital
69.915
+43%
48.820
-47%
91.778
+12%
Balance
168.467
+20%
139.954
-24%
183.982
+0%

Ledelsesberetning

Business activities and mission Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segmenthuman pharmaceuticals. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Our products are sold in approximately 120 countries and globally, Lilly medicines helped 51 million people manage serious and challenging illnesses last year, including diabetes, cancer, migraine, and autoimmune conditions. The activities of Eli Lilly Danmark A/S include the prioritized therapeutic areas Diabetes, Oncology, Neuroscience, and Immunology in Denmark, Finland, Norway, and Iceland. Significant events during the financial year 2022 saw Lilly's product portfolio continue to grow across several key therapeutic areas across the Northern European hub. In Denmark product approvals occurred in our Neurology and Diabetes portfolios. In 2022, the global COVID-19 pandemic once again had significant impact on Lilly's ability to conduct business through in-person channels. Throughout this period, the company has been focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; providing effective treatments for COVID-19; and protecting the health, safety, and well-being of our employees. Throughout the last 12 months, we experienced both a pause and re-engagement of in-person interactions in step with the guidelines imposed across the country according to peaks and waves of the disease. By the end of the year in-person interactions were restored after a significant period of remote working due to COVID-19. Unusual matters The financial statements are not affected by any material unusual matters in 2022. Post financial year events The company's business operations have not been affected by any material adjusting or non-adjusting events after the reporting period. Expected future development Our internal pharmaceutical research focuses primarily on the areas of diabetes, oncology, immunology, neurodegeneration, and pain. In addition to discovering and developing new medicines, we seek to expand the value of existing products through new uses and formulations to provide additional value to patients. Our focus will be to continue the collaboration with authorities to secure patient access to our new molecules and lines extensions. Management expects a positive result for 2023 with profit estimated around DKK 35,000 thousand and forecasted revenue around DKK 700,000 thousand. General risks Eli Lilly's most important operating risks are our ability to get access for new medicines, to protect our IP rights and work successfully with our key stakeholders. Financial risks Due to our solidity and financial preparedness, Eli Lilly Danmark A/S has a limited exposure to changes in interest rates. However, Eli Lilly Danmark A/S is exposed to currency risks related to sales to other Nordic countries. Currency risks As Eli Lilly Danmark A/S invoices our customers in DKK, NOK, and EUR, while a substantial part of the purchase is in DKK, the company is exposed to currency fluctuations and to some currency risks. But the risk is considerate to be non-material to the overall performance. Credit risks Eli Lilly Danmark A/S credit risks primarily relate to financial assets recognized in the balance sheet Accounts Receivables (AR). Eli Lilly Danmark A/S only invoices a few high value customers. To mitigate this risk, all major customers and other collaborators are credit rated on a regular basis. Investments - Research and development activities No major capital investments in Eli Lilly Danmark A/S, besides our ongoing investment in R&D activities, where we conduct multiple studies within Oncology, Diabetes, Neuroscience & autoimmune diseases. These studies are conducted either in-house or outsourced to 'Contract Research Organizations (CROs)', and we contribute to Eli Lilly's overall clinical program. The research is carried out on behalf of the Eli Lilly Group, from which the company received payments on ordinary market terms. In 2022, the company's research and development costs in Denmark was DKK 4,807 thousand. Working Capital The company's financial preparedness amounts to DKK 25,426 thousand at the end of the financial year. The equity ratio is 42% at the end of 2022, compared to 35% end of 2021, corresponding to an equity of DKK 69,916 thousand December 31, 2022, against DKK 48,820 end of 2021. No dividend was paid in 2022. The Board of Directors propose that a dividend of DKK 30,000 thousand is to be paid out in 2023. Net profit/loss for the year compared with previously expressed expectations The annual report for 2022 show a profit before tax of DKK 27,208 thousand compared to a profit before tax of DKK 21,876 thousand in 2021, and in line with the expectations of DKK 24,000 thousand for 2022. Revenue has increased to DKK 605,577 thousand compared to DKK 581,520 thousand in 2021 and is in line with expected DKK 600,000 thousand for 2022. The increase compared to 2021 is due to our resent launched products. We are overall satisfied with the result for 2022. Environmental, Social & Governance cf. §99a The activities of Eli Lilly Danmark A/S consist primarily of distributor of ethical pharmaceutical products developed, patented, and manufactured by other related parties. In addition, Lilly Denmark sells pharmaceutical products to wholesalers in Finland and Norway. Marketing and associated support for these sales is provided by the Lilly entities in those countries. As a distributor of ethical pharmaceutical products, Lilly Denmark is responsible for the distribution, logistics, selling and detailing, marketing and promotion of products. Based on a risk assessment, the company has not identified significant risks with regard to human rights, climate impact, environment, social conditions and employee relations, as well as anti-corruption. As a result, no policies have been drawn up for the respective areas. Data ethics With reference to the requirements under section 99(d) of the Danish Financial Statements Act Eli Lilly Danmark A/S does not have a separate local policy on Data ethics. The reason we do not have a separate policy on Data ethics is that Eli Lilly & Company have several policies describing different aspect of Data ethics such as the use of Real-World Data, Respecting Privacy, Records Management, Publishing Scientific Information, GDPR etc. Gender distribution in management cf. §99b Empowering a diverse workforce, continues to be a key focus area for Lilly, and we are committed to creating and sustaining an open, inclusive, and diverse environment, where all employees feel valued, respected, and heard. Embracing diversity at Lilly means understanding, respecting, and valuing differences, including race, religion, sexual orientation, gender identity, disability status, work style, national origin, and age. In order to foster a strong culture of belonging, there are five employee resource groups actively engaged across the Northern European Hub, including the Gender Inclusion Network which works to remove obstacles that prevent women and men at Lilly from achieving their full potential; Generation-Lilly whose purpose is to promote and embrace a multi-generational culture; ENABLE which has the objective of creating a disability-confident culture; LGBT+Allies which promotes the equal experience, treatment and safety for Lesbian, Gay, Bi and Trans people; and embRACE, which has the purpose of creating an environment where people of colour are empowered to be their authentic selves and a culture where we celebrate differences. At Lilly, our commitment to diversity spans our workplace, but also shapes our understanding of the marketplace, and our relationships with suppliers. A focus on diversity and inclusion is built into our workplace culture. From recruiting and hiring to talent management processes and supervisor coaching, we see direct benefit when our workforce is representative of the customers we serve. We also benefit from each employee's diverse views and ideas. A strong emphasis has been placed on inclusive leadership, unconscious bias education and psychological safety to assist employees to be the best they can be. Gender distribution is part of the workplace diversity commitment, and our goal is to keep a good balance between the genders in all management layers. As per December 31, 2022, the other managerial position consists of the managing director, which is one woman, counted by head count. The Board of Directors persists of two females and one male.

Business activities and mission Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segmenthuman pharmaceuticals. Our purpose is to unite caring with discovery to create medicines that make life better for people around the world. Most of the products we sell today were discovered or developed by our own scientists, and our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines. Our products are sold in approximately 120 countries and globally, Lilly medicines helped 51 million people manage serious and challenging illnesses last year, including diabetes, cancer, migraine, and autoimmune conditions. The activities of Eli Lilly Danmark A/S include the prioritized therapeutic areas Diabetes, Oncology, Neuroscience, and Immunology in Denmark, Finland, Norway, and Iceland. Significant events during the financial year 2022 saw Lilly's product portfolio continue to grow across several key therapeutic areas across the Northern European hub. In Denmark product approvals occurred in our Neurology and Diabetes portfolios. In 2022, the global COVID-19 pandemic once again had significant impact on Lilly's ability to conduct business through in-person channels. Throughout this period, the company has been focused on maintaining a reliable supply of our medicines; reducing the strain on the medical system; providing effective treatments for COVID-19; and protecting the health, safety, and well-being of our employees. Throughout the last 12 months, we experienced both a pause and re-engagement of in-person interactions in step with the guidelines imposed across the country according to peaks and waves of the disease. By the end of the year in-person interactions were restored after a significant period of remote working due to COVID-19. Unusual matters The financial statements are not affected by any material unusual matters in 2022.
29-06-2023

Kort